Metagenomi Therapeutics
MGX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -55.1% in FY2025
Jian Irish, Ph.D., M.B.A. is the CEO of Metagenomi Therapeutics and was paid $1.7M in FY2025 (Dec), down 56%.
Pay$100 in the stock at the end of FY24 → $45
Executives4
See all- 1Jian Irish, Ph.D., M.B.A.President and Chief Executive OfficerFY2025
- 2Brian C. Thomas, Ph.D.Former Chief Executive OfficerFY2025
- 3Pamela Wapnick, M.B.A.Chief Financial OfficerFY2025
- 4Matthew L. Wein, J.D.General Counsel, Compliance Officer, Head of BD&L and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMetagenomi Therapeutics paid its 4 named executives $4.8M in total in FY2025 (Dec). CEO Jian Irish, Ph.D., M.B.A. was paid $1.7M of that.
| Name | |||
|---|---|---|---|
| Jian Irish, Ph.D., M.B.A.President and Chief Executive Officer | |||
| Brian C. Thomas, Ph.D.Former Chief Executive Officer | |||
| Pamela Wapnick, M.B.A.Chief Financial Officer | |||
| Matthew L. Wein, J.D.General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Metagenomi Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Willard H. Dere, M.D.Chair · 4 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair), Research and Development—Paid as an executive
- Eric Bjerkholt, M.B.A.Director · 0 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Laurence Reid, Ph.D.Director · 0 yr on the boardIndependentCompensation (Chair), Nominating and Corporate Governance, Research and Development—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 27, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Mar 17, 2025 | FY2024 |
| Annual report | 10-K | Mar 27, 2024 | FY2023 |
